Zobrazeno 1 - 10
of 30
pro vyhledávání: '"János László, Iványi"'
Publikováno v:
Hematológia–Transzfuziológia. 55:50-53
Bevezetés A T-sejtes nagy granuláris lymphocytás leukémia egy ritka, rett T-sejtes neoplázia, mely változatos klinikai lefolyást mutat és gyakran társul autoimmun szövődményekkel. Esetismertetés Idős férfi betegünknél lymphocytosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1220b87ded4485a18b064df90ef54360
https://doi.org/10.1556/2068.2022.00147
https://doi.org/10.1556/2068.2022.00147
Autor:
Imre Henits, Árpád Vadvári, István Király, János László Iványi, Márk Plander, Gergely Garab, Tamás Szendrei, Ramóna Szöllősi
Publikováno v:
Hematológia−Transzfuziológia. 52:37-44
Absztrakt: Myeloma multiplexes betegek csontlaesioinak pontos detektalasara az egyik legerzekenyebb kepalkoto eljaras a gerinc/csontozatot lekepező diffuziosulyozott magnetikus rezonancia, mely a korai stadium rogzitesere, a terapia hatasossaganak k
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3f783f2d8d6ba239d35dffe8b514409
https://doi.org/10.1556/2068.2019.52.1.7
https://doi.org/10.1556/2068.2019.52.1.7
Autor:
László Kereskai, Béla Kajtár, Gergely Papp, Márk Plander, János László Iványi, Zsuzsanna Szabó, Tamás Szendrei
Publikováno v:
Orvosi Hetilap. 160:502-508
Abstract: Introduction: Prognostic impact of the detection of minimal residual disease (MRD) in multiple myeloma (MM) has been confirmed in numerous studies. Aim: Retrospective examination of our patient database (107 newly diagnosed multiple myeloma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80bbdd1f7c325fe51be2f2c27ff315d5
https://doi.org/10.1556/650.2019.31353
https://doi.org/10.1556/650.2019.31353
Autor:
László Szerafin, Klára Piukovics, Natália Jóni, Ágnes Nagy, Katalin Pál, György Ujj, János László Iványi, Róbert Szász, Árpád Illés, Elvira Altai, Péter Dombi, Zsolt Nagy, Ilona Tárkányi, Tamás Schneider, János Jakucs, Péter Farkas
Publikováno v:
Pathology Oncology Research
Chronic lymphocytic leukemia (CLL) is one of the most common haematological malignancies exhibiting remarkable heterogeneity in clinical course. Rituximab added to standard chemotherapy has been proven to increase response rate and eventually surviva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5ba8f88a7138150375e3fd286260bc9
https://doi.org/10.1007/s12253-018-0474-9
https://doi.org/10.1007/s12253-018-0474-9
Autor:
Zita Borbényi, András Rosta, Judit Demeter, Miklos Egyed, Tamás Schneider, Péter Dombi, Árpád Illés, János Jakucs, László Szerafin, Antal Tóth, György Ujj, Tamás Masszi, János László Iványi, G. Radványi, Hajna Losonczy, Zoltán Gasztonyi
Publikováno v:
Pathology & Oncology Research. 24:199-205
Follicular lymphoma is a lymphoid malignancy commonly showing slow progression which makes the treatment of the disease challenging. Rituximab monotherapy and rituximab added to standard chemotherapy has been proven to increase survival among patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c86f24011c82da085bf56100b06fbe4f
https://doi.org/10.1007/s12253-017-0234-2
https://doi.org/10.1007/s12253-017-0234-2
Autor:
Tamás, Szendrei, Márk, Plander, Zsuzsanna, Szabó, László, Kereskai, Béla, Kajtár, Gergely, Papp, János László, Iványi
Publikováno v:
Orvosi hetilap. 160(13)
Prognostic impact of the detection of minimal residual disease (MRD) in multiple myeloma (MM) has been confirmed in numerous studies.Retrospective examination of our patient database (107 newly diagnosed multiple myelomas between 2007 and 2017). Flow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fb63581fc89765e428e98b93437e3b1c
https://pubmed.ncbi.nlm.nih.gov/30907098
https://pubmed.ncbi.nlm.nih.gov/30907098
Publikováno v:
Orvosi Hetilap. 157:336-341
Introduction: Essential thrombocythemia is a Philadelphia chromosome-negative chronic myeloproliferative neoplasia with a risk of bleeding and thromboembolic complications during the course of illness. Cytoreductive drugs, such as non-selective hydro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81f870f4fc02a9d2df324c396d53e39f
https://doi.org/10.1556/650.2016.30323
https://doi.org/10.1556/650.2016.30323
Autor:
János László Iványi
Publikováno v:
Orvosi Hetilap. 155:638-643
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68a9a9e45993614d9685f3c02cf4125d
https://doi.org/10.1556/oh.2014.16m
https://doi.org/10.1556/oh.2014.16m
Publikováno v:
Pathology & Oncology Research. 26:591-592
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c95dcbfdb2cc3ef158f771a47371225d
https://doi.org/10.1007/s12253-018-0482-9
https://doi.org/10.1007/s12253-018-0482-9
Publikováno v:
Orvosi hetilap. 157(9)
Essential thrombocythemia is a Philadelphia chromosome-negative chronic myeloproliferative neoplasia with a risk of bleeding and thromboembolic complications during the course of illness. Cytoreductive drugs, such as non-selective hydroxyurea or inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ae6e03ad8fdb99ffb1b1868133ed52bc
https://pubmed.ncbi.nlm.nih.gov/26895801
https://pubmed.ncbi.nlm.nih.gov/26895801